Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711346 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells
A Phase 2 study, sponsored by Cerus Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01711346: Completed Phase 2 study, sponsored by Cerus Corporation.
NCT01711346 is a Phase 2 study that has completed, run by Cerus Corporation. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01711346, a Phase 2 study, has completed, sponsored by Cerus Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The objective of this study is to assess the post-infusion viability of S-303 Red Blood Cells (RBC) by measuring the 24 hour post-infusion recovery and lifespan of autologous RBCs prepared with the S-303 Treatment System for RBC after storage for 35 days in comparison to conventional untreated RBCs stored for 35 days.
Primary Outcome
24 hour post-infusion recovery of autologous RBCs stored for 35 days (assessed using the Food and Drug Administration (FDA)) criteria for evaluation of in vivo RBC studies)
Interventions
- BIOLOGICAL S303 Red Blood Cells (RBCs)
- BIOLOGICAL Conventional, untreated Red Blood Cells (RBCs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
What the finished NCT01711346 record still lists
NCT01711346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which S303 Red Blood Cells (RBCs) is the first listed.
NCT01711346 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01711346 about?
NCT01711346 is a clinical study titled "A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells". The objective of this study is to assess the post-infusion viability of S-303 Red Blood Cells (RBC) by measuring the 24 hour post-infusion recovery and lifespan of autologous RBCs prepared with the S-303 Treatment System for RBC after storage for 35 days in comparison to conventional untreated RBCs ...
What is the current status of trial NCT01711346?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2012-10. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01711346?
The interventions under investigation include: S303 Red Blood Cells (RBCs) (BIOLOGICAL), Conventional, untreated Red Blood Cells (RBCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01711346?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01711346's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia